My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions. Conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts, with ease.
About Us
Plans & Pricing
Welcome

Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), Travere Therapeutics (TVTX) and BioNTech SE (BNTX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Zimmer Biomet Holdings (ZBHResearch Report), Travere Therapeutics (TVTXResearch Report) and BioNTech SE (BNTXResearch Report).

Zimmer Biomet Holdings (ZBH)

Leerink Partners analyst Richard Newitter maintained a Buy rating on Zimmer Biomet Holdings on August 30. The company’s shares closed last Wednesday at $150.87.

According to TipRanks.com, Newitter is a 5-star analyst with an average return of 23.2% and a 67.3% success rate. Newitter covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, Organogenesis Holdings, and Intuitive Surgical.

Zimmer Biomet Holdings has an analyst consensus of Strong Buy, with a price target consensus of $189.50, representing a 25.7% upside. In a report issued on August 18, Piper Sandler also maintained a Buy rating on the stock with a $195.00 price target.

See today’s analyst top recommended stocks >>

Travere Therapeutics (TVTX)

Leerink Partners analyst Joseph Schwartz maintained a Buy rating on Travere Therapeutics on August 31 and set a price target of $37.00. The company’s shares closed last Wednesday at $22.13.

According to TipRanks.com, Schwartz is a 4-star analyst with an average return of 12.7% and a 48.2% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Mereo Biopharma Group Plc, and Crinetics Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Travere Therapeutics with a $35.00 average price target, implying a 60.0% upside from current levels. In a report issued on August 16, Canaccord Genuity also maintained a Buy rating on the stock with a $45.00 price target.

BioNTech SE (BNTX)

Leerink Partners analyst Daina Graybosch maintained a Hold rating on BioNTech SE on August 31. The company’s shares closed last Wednesday at $332.50.

According to TipRanks.com, Graybosch is a 3-star analyst with an average return of 7.3% and a 36.2% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Silverback Therapeutics, Bolt Biotherapeutics, and Genocea Biosciences.

BioNTech SE has an analyst consensus of Moderate Buy, with a price target consensus of $321.22, implying a -3.9% downside from current levels. In a report issued on August 17, H.C. Wainwright also reiterated a Hold rating on the stock with a $330.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ZBH: